Stockscreener 앱 받기
25.50
1.32%
-0.34
전일 마감가:
$25.84
열려 있는:
$26.44
하루 거래량:
741.01K
Relative Volume:
0.30
시가총액:
$1.39B
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-30.72
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-10.05%
1개월 성능:
+4.08%
6개월 성능:
+329.29%
1년 성능:
+86.13%
1일 변동 폭
$25.33
$26.58
1주일 범위
$25.12
$28.45
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
25.50 | 1.41B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
CAPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Capricor (CAPR) Faces Challenges Amidst Stricter FDA Approval Pr - GuruFocus
Register: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises - BioSpace
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
CAPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unpacking The 82% Potential Upside - DirectorsTalk Interviews
Capricor Therapeutics (CAPR) Schedule 13G: Suvretta reports 6.6% stake - Stock Titan
A Look At Capricor Therapeutics (CAPR) Valuation As Key Deramiocel Phase 3 Milestones Advance FDA Review - simplywall.st
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference - Bitget
Duchenne trial to showcase Deramiocel Phase 3 data at 2026 MDA meeting - Stock Titan
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Asianet Newsable
Q3 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unveiling a 74% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Trading 12.2% HigherTime to Buy? - MarketBeat
GSA Capital Partners LLP Makes New $1.56 Million Investment in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Highbridge discloses 2.3% Capricor Therapeutics (CAPR) stake via warrants - Stock Titan
What’s the profit margin of Capricor Therapeutics IncEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Aug PostEarnings: Whats the profit margin of Capricor Therapeutics IncForecast Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: A 114% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Breakout Move: Whats the profit margin of Capricor Therapeutics Inc2025 Bull vs Bear & Weekly Momentum Stock Picks - baoquankhu1.vn
Why Capricor Therapeutics Inc. stock could see breakout soonEarnings Growth Summary & Long-Term Capital Growth Strategies - mfd.ru
How cyclical is Capricor Therapeutics Inc.’s revenue streamWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment - BioSpace
(CAPR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving AverageTime to Sell? - MarketBeat
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
A Look At Capricor Therapeutics (CAPR) Valuation After Its New Shelf Registration Filing - Sahm
Phase III wins propel Capricor, Belite and DBV higher in December - BioWorld MedTech
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Capric - GuruFocus
Capricor Therapeutics, Inc. (CAPR): Uncovering the 124.68% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.7%Here's Why - MarketBeat
Does FDA’s No-New-Trial Stance on Deramiocel Shift the Bull Case for Capricor Therapeutics (CAPR)? - Sahm
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving AverageShould You Sell? - MarketBeat
(CAPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Advances Review Of Deramiocel BLA - Sahm
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - MSN
Tang Capital group reports 6.6% Capricor (NASDAQ: CAPR) ownership on Schedule 13G - Stock Titan
Highs Report: Whats the profit margin of Capricor Therapeutics IncBull Run & Weekly Stock Breakout Alerts - baoquankhu1.vn
Capricor Therapeutics, Inc. (CAPR): Investor Outlook On Promising 110% Upside Potential - DirectorsTalk Interviews
CAPR stock slides after FDA requests more data for genetic disorder therapy — what does retail think? - MSN
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February - TradingView — Track All Markets
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics (CAPR)? - Sahm
Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? - Yahoo Finance
Is Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump - Yahoo Finance
Capricor Updates Deramiocel BLA Status After FDA Review of HOPE-3 Data - filmogaz.com
Capricor Therapeutics (CAPR) Valuation After FDA Requests HOPE-3 Data For Deramiocel Regulatory Review - Yahoo Finance
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):